10-Q: Carlsmed Q3 2025: Revenue Soars 98% Post-IPO, Cervical Launch Nears

Carlsmed, Inc. reports significant revenue growth and gross margin improvement in Q3 2025, driven by increased adoption of its aprevo Technology Platform and successful IPO, despite continued operating losses.

Summary

• Revenue for the three months ended September 30, 2025, was $13.1 million, representing a 98.4% increase compared to $6.6 million for the same period in 2024.
• Revenue for the nine months ended September 30, 2025, was $35.3 million, representing a 99.1% increase compared to $17.8 million for the same period in 2024.
• Gross margin improved to 75.9% for the three months ended September 30, 2025, up from 72.8% in the prior year period, and to 74.8% for the nine months, up from 73.3%.
• Net loss for the three months ended September 30, 2025, was $(8.5) million, compared to $(7.8) million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $(21.0) million, compared to $(19.5) million for the same period in 2024.
• The company completed its Initial Public Offering (IPO) on July 24, 2025, raising $93.5 million in net proceeds.
• Cash and cash equivalents stood at $115.4 million as of September 30, 2025.
• The FDA granted 510(k) clearance for the aprevo Technology Platform for cervical spine fusion surgery in November 2024, with the first procedure successfully completed in July 2025.
• Over 50 aprevo cervical procedures have been successfully completed by over a dozen spine surgeons as part of a clinical evaluation program through October 31, 2025.
• The Digital Production System (DPS) lead time for aprevo interbody implants was reduced to eight business days from 10 business days starting October 2025.
• CMS adopted new MS-DRG coding effective October 2024, providing premium reimbursement for lumbar spine fusion procedures utilizing custom-made interbody fusion devices like aprevo.
• Cervical fusion procedures utilizing aprevo personalized interbody implants are eligible for New Technology Add-on Payments (NTAPs) from CMS effective October 1, 2025, offering up to an additional $21,125 in reimbursement for eligible inpatient procedures.
• The Customers Loan Agreement was amended on October 29, 2025, expanding the credit facility to a term loan of up to $50.0 million and a $10.0 million non-formula revolving line of credit, extending the term loan maturity to October 15, 2030.

Sentiment

Score: 8

Explanation: The company demonstrates exceptional revenue growth and improving gross margins, indicating strong market adoption of its innovative AI-enabled spine surgery platform. The successful IPO significantly bolstered its financial position, and recent FDA clearances and favorable reimbursement changes for its expanded product portfolio (cervical spine) provide strong tailwinds for future growth. While operating losses persist, they are expected as the company scales its commercial operations and invests in R&D.

Positives

• Achieved strong revenue growth of 98.4% in Q3 2025 and 99.1% for the nine months ended September 30, 2025, indicating robust market adoption.
• Improved gross margin to 75.9% in Q3 2025 (from 72.8%) and 74.8% for the nine months (from 73.3%), driven by production efficiencies and reduced inventory reserve expenses.
• Successfully completed an Initial Public Offering (IPO) in July 2025, raising $93.5 million in net proceeds, significantly strengthening the company's liquidity.
• Cash and cash equivalents increased substantially to $115.4 million as of September 30, 2025, providing a strong capital base.
• Received FDA 510(k) clearance for the aprevo Technology Platform for cervical spine fusion surgery in November 2024, expanding the product portfolio and addressable market.
• Successfully completed over 50 aprevo cervical procedures by October 31, 2025, demonstrating early clinical adoption and positive surgeon feedback.
• Favorable CMS reimbursement changes, including new MS-DRG coding for lumbar procedures (effective October 2024) and NTAP eligibility for cervical procedures (effective October 1, 2025), are expected to enhance demand and hospital profitability.
• Anticipated Transitional Pass-Through (TPT) payment for cervical procedures in hospital outpatient departments (HOPDs) and ambulatory surgery centers (ASCs) in early 2026 will further support adoption.
• Reduced Digital Production System (DPS) lead time to eight business days from 10 business days starting October 2025, improving operational efficiency and delivery speed.
• Expanded credit facility with Customers Bank to up to $50.0 million term loan and a $10.0 million revolving line of credit, with extended maturity to October 15, 2030, providing additional financial flexibility.

Negatives

• Continued to incur net losses, with $(8.5) million in Q3 2025 and $(21.0) million for the nine months ended September 30, 2025.
• Experienced negative cash flows from operating activities, totaling $(23.7) million for the nine months ended September 30, 2025.
• Maintains a significant accumulated deficit of $92.2 million as of September 30, 2025.
• General and administrative expenses increased by 155.8% in Q3 2025 and 93.1% for the nine months, partly due to increased costs associated with operating as a public company.
• Sales and marketing expenses increased by 45.1% in Q3 2025 and 60.5% for the nine months, reflecting substantial investment in commercial expansion.

Risks

• Ability to advance the aprevo Technology Platform and any potential future products through applicable regulatory approval processes.
• Existing regulations and regulatory developments in the United States and other jurisdictions.
• Ability to maintain or improve third-party payor reimbursement strategy.
• Ability to attract and retain hospitals and surgeons.
• Reliance on a limited number of Contract Manufacturing Organizations (CMOs).
• Ability to maintain competitive technological advantages.
• Ability to effectively manage growth.
• Increased expenses associated with being a public company.
• Estimates of expenses, future revenue, capital requirements, needs for additional financing, and ability to obtain additional capital.
• Fluctuations in quarterly and annual financial results may decrease the value of common stock.
• Potential for significant dilution if additional funds are raised through further issuances of equity or convertible debt securities.
• Incurrence of indebtedness could increase fixed obligations and include covenants or other restrictions that would impede the ability to manage operations.
• Ability to raise additional funds may be adversely impacted by deteriorating global economic conditions and volatility in credit and financial markets.
• Litigation or other claims against the company for intellectual property infringement or otherwise.
• Expenses associated with unforeseen product quality issues.

Future Outlook

The company expects to continue generating operating losses for the foreseeable future as it expands commercial operations and develops its product portfolio. Existing cash on hand is believed to be sufficient to meet anticipated capital requirements for at least 12 months. The company plans to commercialize the aprevo Technology Platform for cervical fusion surgery by early 2026 and intends to pursue adjacent and international markets. Gross margin is expected to modestly increase over the medium and long term due to economies of production scale and increased leverage of AI technologies. Research and development, sales and marketing, and general and administrative expenses are anticipated to increase in absolute value but decrease as a percentage of revenue over time.

Management Comments

• "We are a commercial-stage medical technology company pioneering artificial intelligence (AI)-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond."
• "We are focused on becoming the standard of care for spine fusion surgery."
• "We expect to commercialize the aprevo Technology Platform for cervical fusion surgery by early 2026."
• "We believe that our existing cash on hand will be sufficient to meet anticipated capital requirements for its operations for at least 12 months from the date of the issuance of the accompanying Condensed Financial Statements."

Industry Context

Carlsmed operates in the highly innovative surgical device sector, specifically targeting spine fusion surgery with its AI-enabled personalized aprevo Technology Platform. This approach aims to address limitations of traditional stock implants by optimizing patient outcomes and reducing revision surgeries, positioning the company as a leader in personalized medicine within orthopedics. The recent FDA Breakthrough Device Designations for both lumbar and cervical applications, coupled with new CMS reimbursement codes (MS-DRG, NTAP, TPT), indicate a supportive regulatory and reimbursement environment for such innovative medical technologies. This favorable landscape is expected to accelerate market adoption and penetration for Carlsmed, aligning with broader industry trends towards value-based care and advanced surgical solutions.

Comparison to Industry Standards

• Clinical data presented at the Scoliosis Research Society (SRS) Annual Meeting in September 2025 demonstrated a 75% reduction in spine fusion revision surgery at two years for 115 aprevo-treated Adult Spinal Deformity (ASD) patients compared to a patient-matched cohort treated with stock interbody devices, indicating superior clinical outcomes.
• The FDA awarded aprevo lumbar interbody implants a Breakthrough Device Designation in July 2020, and aprevo cervical spine fusion received its second Breakthrough Device Designation in September 2023, signifying that the technology is likely to provide a more effective treatment than existing alternatives.

Corporate Governance

Legal Proceedings

• The company is involved in legal matters incidental to the conduct of its business from time to time. In the opinion of management, there are no claims outstanding that would have a material adverse effect on the company's financial position, results of operations, or cash flows.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue growth, gross margin improvement, successful IPO, and expanded product pipeline. Potential for dilution from future capital raises.
• Employees: Continued investment in the workforce through increased personnel costs and stock-based compensation. New 2025 Equity Incentive Plan provides incentives.
• Customers (Hospitals/Surgeons): Benefits from reduced lead times for implants (8 business days), expanded product offerings (cervical spine), and favorable reimbursement changes (premium for lumbar, NTAP/TPT for cervical) which make using aprevo more financially attractive.
• Creditors (Customers Bank): Loan agreement expanded and maturity extended, indicating continued relationship and confidence.
• Patients: Benefits from personalized implants, improved surgical outcomes (75% reduction in revision surgery for ASD patients), and expanded treatment options (cervical spine).

Next Steps

• Commercialize the aprevo Technology Platform for cervical fusion surgery by early 2026.
• Receive FDA clearance for accompanying personalized plating solutions for cervical spine fusion.
• Drive initial adoption of the new cervical indication among existing surgeons.
• Evaluate strategic international regions for market access initiatives.
• Continue to accelerate product and software innovation and develop additional clinical data.
• Expand manufacturing capabilities.
• Grow commercial infrastructure and expand market access initiatives, including medical education programs and surgeon training.
• Build upon clinical evidence demonstrating efficacy of the aprevo Technology Platform.
• Monitor and adapt to future changes in reimbursement levels from payors.
• Achieve additional revenue milestones to extend interest-only period and repayment terms of the Term Loan.

Key Dates

Recommendation

The company is demonstrating exceptional revenue growth (nearly 100% year-over-year) and improving gross margins, indicating strong market adoption of its innovative AI-enabled spine surgery platform. The recent IPO has significantly strengthened its balance sheet, providing ample capital for continued commercial expansion and R&D. Key regulatory clearances for cervical spine fusion and favorable CMS reimbursement changes (NTAP, new MS-DRG codes) are powerful catalysts that will drive future demand and profitability. While the company is still operating at a loss, this is typical for a high-growth medical technology company in its commercialization phase, and the underlying business fundamentals and strategic positioning are very strong. The clinical data showing a 75% reduction in revision surgery is a compelling differentiator.

Keywords

Carlsmed, aprevo, spine surgery, medical technology, AI-enabled surgery, spinal implants, lumbar fusion, cervical fusion, FDA clearance, IPO, financial results, Q3 2025, medtech, surgical device, orthopedics, reimbursement, NTAP, TPT